Polyethylene Glycol 400

The dosage of Polyethylene Glycol 400 varies significantly based on the condition being treated and the formulation used.

Ophthalmic Use (Dry Eye)

For the relief of dry eye symptoms, the standard dosage is 1 to 2 drops in the affected eye(s) as needed. Many patients find relief with 3 to 4 applications daily, though it can be used more frequently if the formulation is preservative-free. If you are using PEG 400 for chronic dry eye, your ophthalmologist may recommend a specific schedule to maintain the integrity of the tear film.

Systemic/Excipient Use

When PEG 400 is used as a solvent in oral medications, the dose is determined by the active ingredient (e.g., the amount of PEG 400 in a 200 mg ibuprofen liquid gel). There is no independent 'dosage' for PEG 400 in these cases, but the total daily intake of PEG 400 should generally not exceed 10 mg/kg of body weight to avoid potential osmotic effects in the gut.

Polyethylene Glycol 400 is generally considered safe for pediatric use when applied topically as an eye drop. For children under the age of 6, it is recommended to consult a pediatrician before use to ensure the symptoms are not related to an underlying infection or injury. Systemic use of PEG 400 in children is typically limited to its role as an excipient in FDA-approved pediatric medications. Specific weight-based dosing for 'Calculi Dissolution' or 'Plasma Volume Expansion' in children must be strictly managed by a specialist in a hospital setting.

Renal Impairment

Because PEG 400 is primarily eliminated by the kidneys, patients with severe renal impairment (CrCl < 30 mL/min) should be monitored if receiving high doses of systemic PEG 400 (such as in certain IV drug formulations). Accumulation of PEG can lead to increased serum osmolality and potential metabolic complications.

Hepatic Impairment

No dosage adjustments are typically required for patients with hepatic impairment, as the liver plays a minimal role in the clearance of Polyethylene Glycol 400.

Elderly Patients

Older adults are more prone to dry eye syndrome and may use PEG 400 frequently. While no specific dose adjustment is needed, elderly patients should be cautioned about the risk of blurred vision immediately after application, which may increase the risk of falls.

Ophthalmic Administration

1. 1Wash your hands thoroughly before use.
2. 2Tilt your head back and pull down the lower eyelid to create a small pocket.
3. 3Hold the dropper above the eye without touching the tip to the eye, eyelid, or any other surface (to prevent contamination).
4. 4Squeeze the prescribed number of drops into the pocket.
5. 5Close your eyes for 1-2 minutes and apply gentle pressure to the corner of the eye (punctal occlusion) to prevent the liquid from draining into the tear duct.
6. 6If using other eye medications, wait at least 5-10 minutes between applications.

Storage Conditions

Store Polyethylene Glycol 400 products at room temperature, typically between 15°C and 30°C (59°F to 86°F). Keep the container tightly closed when not in use. Protect from excessive heat and direct light.

If you are using PEG 400 on a schedule and miss a dose, apply it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up.

An overdose of ophthalmic Polyethylene Glycol 400 is unlikely to cause serious systemic effects. However, excessive use may cause temporary irritation or blurred vision. If the solution is accidentally swallowed, especially by a child, contact a Poison Control Center immediately. Symptoms of oral overdose may include diarrhea, abdominal cramping, and dehydration due to the osmotic effect of the polymer in the intestines.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Polyethylene Glycol 400 is generally well-tolerated, especially in topical ophthalmic forms. However, the most common side effects include:

• Transient Blurred Vision: This typically occurs immediately after the drops are instilled. It usually lasts for 30 seconds to 2 minutes as the polymer spreads across the ocular surface.
• Mild Eye Irritation: A brief sensation of stinging or burning may occur upon application. This is often due to the difference in pH or osmolality between the drops and the patient's natural tears.
• Eye Discharge: A small amount of 'crusting' or clear discharge may be noticed on the eyelashes after the solution dries.

• Eye Redness (Hyperemia): Some patients may experience mild redness of the conjunctiva (the white part of the eye).
• Increased Sensitivity to Light (Photophobia): If the eye is already irritated, the addition of a viscous lubricant may temporarily increase light sensitivity.
• Watery Eyes: Paradoxically, the eye may produce more natural tears in response to the introduction of a foreign substance.

• Eyelid Swelling (Edema): This may indicate a mild localized inflammatory response.
• Headache: Rarely reported with intensive use of ophthalmic lubricants.
• Allergic Contact Dermatitis: If PEG 400 is used in topical skin creams, a small percentage of the population may develop a red, itchy rash at the site of application. This is why it is classified as a Non-Standardized Chemical Allergen [EPC].

While extremely rare, serious reactions can occur.

> Warning: Stop taking Polyethylene Glycol 400 and call your doctor immediately if you experience any of these:

• Anaphylaxis: Signs include hives, difficulty breathing, swelling of the face, lips, tongue, or throat. This is a medical emergency.
• Severe Eye Pain: If the pain is sharp, stabbing, or persistent after using the drops.
• Vision Changes: Any sudden loss of vision or the appearance of 'halos' around lights.
• Signs of Systemic Toxicity: If PEG 400 is absorbed in large quantities (usually through large open wounds or high-dose IV use), it can lead to Acute Kidney Injury (AKI). Symptoms include decreased urination, swelling in the legs, and confusion.
• Metabolic Acidosis: This is a condition where too much acid builds up in the body. Symptoms include rapid breathing, extreme fatigue, and a racing heart.

Long-term use of Polyethylene Glycol 400 in the eyes is generally considered safe. However, if the formulation contains preservatives (such as Benzalkonium Chloride), chronic use (more than 4-6 times daily) may lead to 'medicamentosa,' a condition where the preservatives themselves cause damage to the corneal epithelium. In such cases, switching to a preservative-free formulation is necessary. There is no evidence that long-term use of PEG 400 leads to systemic accumulation in healthy individuals.

No FDA black box warnings currently exist for Polyethylene Glycol 400. It is regarded as one of the safest polymers used in medical practice. However, healthcare providers caution against its use in patients with known hypersensitivity to any polyethylene glycol derivative.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Polyethylene Glycol 400 is a highly stable and safe compound, but its use requires adherence to specific safety protocols to prevent complications. The most critical safety concern with ophthalmic use is the risk of secondary infection. If the tip of the dispensing bottle touches any surface, including the eye itself, it can become contaminated with bacteria or fungi, leading to serious ocular infections such as bacterial keratitis.

No FDA black box warnings for Polyethylene Glycol 400. It has a long-standing safety record when used according to label instructions.

Allergic Reactions / Anaphylaxis Risk

While PEG 400 is often used as a 'hypoallergenic' vehicle, a small subset of the population has developed anti-PEG antibodies. This can lead to hypersensitivity reactions ranging from mild urticaria (hives) to life-threatening anaphylaxis. Patients who have had reactions to other PEG-containing products (like certain mRNA vaccines or bowel prep kits) should use PEG 400 with caution.

Nephrotoxicity Risk

In clinical scenarios where PEG 400 is applied to large areas of denuded skin (such as in severe burn patients), there is a risk of systemic absorption. Historical data has shown that excessive absorption of low-molecular-weight PEGs can lead to renal tubular necrosis. Healthcare providers should monitor kidney function in patients with compromised skin integrity receiving PEG-based topicals.

Ocular Condition Masking

Patients should not use Polyethylene Glycol 400 as a substitute for professional medical care. If eye pain, changes in vision, or persistent redness occurs, the patient must be evaluated for more serious conditions like glaucoma, uveitis, or corneal abrasions.

For standard OTC ophthalmic use, no routine laboratory monitoring is required. However, for specialized uses:

• Renal Function: Patients receiving systemic PEG-based therapies should have their Serum Creatinine and Blood Urea Nitrogen (BUN) monitored.
• Serum Osmolality: In cases of suspected PEG toxicity, calculating the osmolal gap can help determine the level of systemic polymer accumulation.

Polyethylene Glycol 400 eye drops can cause temporary blurring of vision. Patients should wait until their vision is completely clear before driving a motor vehicle or operating heavy machinery. This typically takes only a few minutes but is a critical safety consideration.

There are no known direct interactions between alcohol consumption and topical Polyethylene Glycol 400. However, alcohol can exacerbate systemic dehydration and dry eye symptoms, potentially reducing the perceived efficacy of the lubricant.

There is no withdrawal syndrome associated with Polyethylene Glycol 400. Patients can stop using the product at any time. However, the symptoms of dry eye or irritation are likely to return once the lubricating film is no longer being replenished.

> Important: Discuss all your medical conditions with your healthcare provider before starting Polyethylene Glycol 400.

There are no absolute contraindications for the use of Polyethylene Glycol 400 with other drugs. However, it should not be mixed directly in the same container with other medications unless specifically directed by a pharmacist, as it may alter the chemical stability of the other drug.

Ophthalmic Medications

When used with other medicated eye drops (such as those for glaucoma or infections), PEG 400 can potentially alter the penetration of the active drug. The viscous film created by PEG 400 may act as a barrier, reducing the absorption of the second medication.

• Management: Always wait at least 10 minutes between the application of PEG 400 and any other ophthalmic drug.

Systemic Nephrotoxic Agents

If PEG 400 is being absorbed systemically (e.g., through damaged skin), using it alongside other nephrotoxic drugs (like aminoglycoside antibiotics or NSAIDs) may theoretically increase the risk of kidney strain.

• Mechanism: Combined osmotic load and potential for tubular interference.
• Management: Monitor renal parameters closely.

Preservatives (Benzalkonium Chloride)

PEG 400 is often formulated with preservatives. In some cases, the polymer can form complexes with these preservatives, slightly altering their antimicrobial efficacy or increasing their retention time on the ocular surface.

• Clinical Consequence: Increased risk of surface toxicity with very frequent dosing.

There are no documented interactions between Polyethylene Glycol 400 and specific foods. Unlike some medications, its absorption (when used as an oral excipient) is not significantly affected by dairy or high-fat meals.

No significant interactions have been identified with common herbal supplements like St. John's Wort or Ginkgo Biloba. However, supplements that have a diuretic effect (like dandelion root) may worsen the underlying dry eye condition that PEG 400 is intended to treat.

Polyethylene Glycol 400 can interfere with certain laboratory tests if present in high concentrations in the blood:

• Serum Osmolality: PEG 400 is osmotically active and will increase the measured osmolality, leading to an 'osmolal gap.'
• Ethylene Glycol Screens: Some older gas chromatography methods for detecting antifreeze (ethylene glycol) poisoning may show a false positive or interference in the presence of high levels of PEG 400.
• Urine Specific Gravity: Can be falsely elevated if PEG 400 is being excreted in large amounts.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Polyethylene Glycol 400 must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity: Patients with a documented allergy to Polyethylene Glycol 400 or any other PEG derivative (such as PEG 3350, Macrogol, or Polysorbate 80) must avoid this substance. The mechanism is an IgE-mediated or T-cell mediated immune response that can lead to anaphylaxis.
2. 2Ocular Infection (Untreated): While not a chemical contraindication, using PEG 400 as a self-treatment for a red eye that is actually caused by a bacterial, viral, or fungal infection can delay necessary antibiotic treatment and potentially worsen the infection by trapping pathogens against the cornea.

Conditions requiring careful risk-benefit analysis include:

• Severe Renal Failure: As discussed, systemic absorption can lead to accumulation. The risk must be weighed against the benefit of the medication that PEG 400 is carrying.
• Deep Puncture Wounds or Serious Burns: The risk of systemic absorption of the polymer is significantly higher when the skin barrier is absent. Healthcare providers may prefer non-PEG-based dressings or lubricants in these cases.
• Contact Lens Wear: Some formulations of PEG 400 are not compatible with soft contact lenses, as the polymer or the preservatives can bind to the lens material, causing clouding or irritation. Patients should check the specific product label regarding 're-wetting' vs. 'lubricating' drops.

Patients allergic to PEG 400 may also react to:

• Polysorbates (common in vaccines and processed foods).
• PEGylated drugs (such as Pegasys or Neulasta).
• Bowel prep kits (MoviPrep, GoLYTELY).

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Polyethylene Glycol 400.

Polyethylene Glycol 400 is generally classified as Pregnancy Category C (or equivalent under newer labeling systems). This means that while there are no adequate, well-controlled studies in pregnant women, animal studies have not shown significant teratogenic effects at standard doses. Because systemic absorption from the eye is negligible, the risk to the fetus is considered extremely low. However, it should only be used during pregnancy if clearly needed and after discussion with a healthcare provider. There is no evidence that PEG 400 affects fertility or causes trimester-specific risks.

It is not known whether Polyethylene Glycol 400 is excreted in human milk. However, given its high molecular weight (even at 400 Da) and minimal systemic absorption from topical routes, it is highly unlikely that clinically significant amounts would reach the nursing infant. The risk-benefit ratio usually favors the use of PEG 400 for maternal dry eye symptoms during lactation.

PEG 400 is widely used in pediatric populations, primarily in eye drops and as an excipient in liquid medications. It is generally considered safe for children. However, the 'Plasma Volume Expander' and 'Calculi Dissolution' uses are specialized and not standard for pediatric care outside of clinical trials or emergency hospital settings. Parents should ensure that children do not touch the dropper tip to prevent eye infections.

Elderly patients are the primary users of PEG 400 due to the high prevalence of age-related dry eye. While safe, clinicians should be aware of 'Polypharmacy concerns.' If an elderly patient is using multiple eye drops for glaucoma, the addition of PEG 400 must be timed correctly to avoid washing out the glaucoma medication. Additionally, reduced renal clearance in the elderly means that systemic exposure (if any) will last longer.

In patients with a GFR < 60 mL/min, caution is advised if PEG 400 is being used systemically or over large areas of broken skin. While no specific dose-adjustment table exists for PEG 400, monitoring for an increased osmolal gap is the standard clinical approach in high-exposure cases.

No adjustments are necessary for patients with liver disease. The pharmacokinetics of PEG 400 are independent of hepatic function.

> Important: Special populations require individualized medical assessment.

Polyethylene Glycol 400 is a non-ionic surfactant and polymer. Its primary clinical effect is derived from its hydrophilicity. Each molecule of PEG 400 contains multiple oxygen atoms that act as hydrogen bond acceptors, allowing it to bind and retain water. On the ocular surface, it integrates into the mucin layer of the tear film, enhancing the 'wetting' of the corneal epithelium. This reduces surface tension and provides a viscoelastic shield. In its role as a Calculi Dissolution Agent [EPC], it acts as a solvent that can disrupt the ionic bonds in calcium-based stones through weak chelation and pH modification.

The onset of action for Polyethylene Glycol 400 eye drops is nearly immediate, providing relief within seconds of application. The duration of effect is typically 2 to 4 hours, depending on the severity of the dry eye and the rate of tear turnover. It does not target specific receptors (like G-protein coupled receptors) but rather acts through physical and osmotic properties. No tolerance development has been reported; the drug remains effective with repeated use.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Topical); ~60% (Oral) |

| Protein Binding | 0% |

| Half-life | 2 - 4 hours (Systemic) |

| Tmax | 1 - 2 hours (Oral) |

| Metabolism | Minimal (Alcohol Dehydrogenase) |

| Excretion | Renal 80-90% (Unchanged) |

• Molecular Formula: H(OCH2CH2)nOH (where n = 8.2 to 9.1)
• Molecular Weight: 380 – 420 g/mol
• Solubility: Highly soluble in water, ethanol, and acetone.
• Structure: A linear polymer of ethylene oxide units with terminal hydroxyl groups. Its low molecular weight keeps it in a liquid state at room temperature.

Polyethylene Glycol 400 is classified as an Ophthalmic Lubricant and an Osmotic Agent. Within the EPC framework, it is recognized as a Plasma Volume Expander, a Non-Standardized Chemical Allergen, and a Calculi Dissolution Agent. It is chemically related to other PEGs like PEG 3350 (MiraLAX) and PEG 4000, though its lower molecular weight gives it unique permeability and viscosity characteristics.